CSPC PHARMA (01093.HK): NDA for Envi Trastuzumab Injection Accepted by NMPA
NewTimeSpace News: CSPC Pharma (01093.HK) released a voluntary announcement on 17 July 2026. The New Drug Application for Envi Trastuzumab Injection developed by the Group has been accepted by the National Medical Products Administration (NMPA). Classified as a Class 1 therapeutic biological product, the candidate is indicated for adult patients with unresectable or metastatic HER2-positive breast cancer who have received one or more prior anti-HER2 therapies.
NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.
- CSPC PHARMA(01093.HK): Phase II Clinical Trial of SYH2070 Injection for Mixed Hyperlipidaemia Initiated at First Clinical Site in China
- CSPC PHARMA(01093.HK): Enters Collaboration, Option and Licence Agreement with AstraZeneca for siRNA Drug Development with USD30 Million Upfront Payment
- CSPC PHARMA(01093.HK): Phase III Study of Anistolimab Combined with HB1801 for HER2-positive Advanced Breast Cancer Meets Primary Endpoint
- CSPC PHARMA(01093.HK): 2026 Q1 Report - Profit Attributable to Shareholders stood at CNY 859.79 million, YoY decrease of 41.83%
- CSPC PHARMA(01093.HK): Antibody-Drug Conjugate SYS6051 Approved for Clinical Trials for Advanced Solid Tumors
